Monte Rosa tumbles on read-through from Novo's cardiovascular trial failure

Monte Rosa Therapeutics

31/07/2026 16:05

** Shares of Monte Rosa Therapeutics GLUE.O fall 31.5% to four-month low of $15.54
** Novo Nordisk's NOVOb.CO says its experimental drug, ziltivekimab, failed to reduce the risk of major cardiovascular events versus placebo in a late-stage trial
** Monte Rosa is developing MRT-8102 for atherosclerotic cardiovascular disease, the same disease targeted in Novo's trial
** Novo tested ziltivekimab, an anti-IL-6 antibody, while MRT-8102 is a NEK7 degrader that works upstream in the NLRP3/inflammasome pathway
** Wedbush analyst Robert Driscoll says Novo's trial failure "has significant relevance to GLUE's NEK7 degrader program MRT-8102"
** Driscoll says he is "removing credit for MRT-8102 from our valuation" because clinical de-risking will likely be delayed
** "We expect investors to reduce/remove risk-adjusted value the MRT-8102" opportunity in cardiovascular - Guggenheim analyst
** U.S.-listed shares of Novo Nordisk NVO.N down 9%
** As of last close, GLUE down 0.2% YTD

(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))